BCL2 and chronic myelogenous leukemia, BCR-ABL1 positive: With overexpression of BCL-2 in CML-MBP and preclinical data showing synergy of venetoclax and BCR-ABL targeting TKIs in eradication of leukemic stem cells, this potent combination could improve response rates for CML-MPB patients.